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Intellectual Disability - four novel mutations and
two novel syndromic phenotypes
Anju K Philips1, Auli Sirén2, Kristiina Avela3, Mirja Somer3, Maarit Peippo3, Minna Ahvenainen1, Fatma Doagu1,
Maria Arvio5, Helena Kääriäinen4,6, Hilde Van Esch7, Guy Froyen8, Stefan A Haas9, Hao Hu10, Vera M Kalscheuer10
and Irma Järvelä1*Abstract
Background: X-linked intellectual disability (XLID) is a group of genetically heterogeneous disorders characterized
by substantial impairment in cognitive abilities, social and behavioral adaptive skills. Next generation sequencing
technologies have become a powerful approach for identifying molecular gene mutations relevant for diagnosis.
Methods & objectives: Enrichment of X-chromosome specific exons and massively parallel sequencing was
performed for identifying the causative mutations in 14 Finnish families, each of them having several males affected
with intellectual disability of unknown cause.
Results: We found four novel mutations in known XLID genes. Two mutations; one previously reported missense
mutation (c.1111C > T), and one novel frameshift mutation (c. 990_991insGCTGC) were identified in SLC16A2, a gene
that has been linked to Allan-Herndon-Dudley syndrome (AHDS). One novel missense mutation (c.1888G > C) was
found in GRIA3 and two novel splice donor site mutations (c.357 + 1G > C and c.985 + 1G > C) were identified in the
DLG3 gene. One missense mutation (c.1321C > T) was identified in the candidate gene ZMYM3 in three affected males
with a previously unrecognized syndrome characterized by unique facial features, aortic stenosis and hypospadia was
detected. All of the identified mutations segregated in the corresponding families and were absent in > 100 Finnish
controls and in the publicly available databases. In addition, a previously reported benign variant (c.877G > A) in SYP
was identified in a large family with nine affected males in three generations, who have a syndromic phenotype.
Conclusions: All of the mutations found in this study are being reported for the first time in Finnish families with
several affected male patients whose etiological diagnoses have remained unknown to us, in some families, for more
than 30 years. This study illustrates the impact of X-exome sequencing to identify rare gene mutations and the
challenges of interpreting the results. Further functional studies are required to confirm the cause of the syndromic
phenotypes associated with ZMYM3 and SYP in this study.Background
Intellectual disability (ID) can be defined as a significant
impairment of cognitive and adaptive functions and has an
estimated prevalence of 1.5-2% [1]. It is defined by an
intelligence quotient (IQ) below 70 and an impairment in
social and adaptive skills diagnosed before the age of
18 years [2]. ID can be caused by genetic as well as Anon-* Correspondence: irma.jarvela@helsinki.fi
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Helsinki, Finland
Full list of author information is available at the end of the article
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unless otherwise stated.genetic factors. A consistent finding among individuals
with ID has been the excess of males [1], indicating a role
of defects on the X-chromosome. Mutations in X-linked
genes contribute for 10%-15% of ID cases in males [3].
There is substantial evidence that X-linked ID (XLID) is
genetically an extremely heterogeneous disorder [4].
The recent development of sequencing technologies
has provided an effective tool to analyze the chromo-
somal distribution of mutations underlying ID [5-10].
Sequencing of the coding regions of the X-chromosome
in families with multiple affected males has resulted inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Also in sporadic male patients, the possibility of a de novo
mutation on the X-chromosome has to be taken into
consideration [12].
The aim of this study was to identify the causative gene
defects underlying XLID in Finnish families with two or
more affected males.
Methods
Patients
Families with two or more affected males with ID were
enrolled in this study (n = 14). Many of these patients
have been under the care of experienced child neurolo-
gists and/or clinical geneticists since 1980. Inspite of
detailed clinical investigations the diagnosis for these
families has remained unknown. The Ethical Committee
of the Helsinki University Central Hospital approved this
study. Written informed consent was obtained from
either the parents or the guardians of the patients.
DNAs from Finnish blood donors were used as controls.
Exome sequencing
For enrichment of genomic DNA from 11 index patients
we used the Agilent SureSelect Human X-Chromosome
Exome kit (Agilent, California, USA) and for three index
patients (D299, D301, D303) we performed droplet-based
multiplex PCR (7,367 amplicons, 757 genes, 1.54 Mb)
similarly to the previously described study [13]. DNAs
were sequenced on the Illumina GAII and HiSeq2000
platforms, respectively. For all samples coverage of at least
10X was reached for >86% of the targeted regions. Average
sequencing depth ranged between 149–583. The sequence
files were then aligned against the hg19 reference genome
by SOAP2.21 with the default settings. Variants in the
form of SNVs, indels and CNVs were called by an in house
software package (Medical Re-sequencing Analysis Pipe-
line (MERAP), developed at the Max Planck Institute for
Molecular Genetics, Berlin. All sequence variants were
screened against publicly available databases (dbSNP138,
1000 Genomes project, Exome Variant Server (ESP6500)
and the in-house database of the Max Planck Institute,
Berlin) for annotating likely non-pathogenic and previ-
ously reported neutral variants. In addition, the OMIM
catalogue and the Human Gene Mutation Database
(HGMD) were used as a filter to identify all previously
described pathogenic changes.
Mutation analysis and Sanger sequencing
Validation of variants was performed using the standard
Sanger sequencing protocol. First, primers (Oligomer Ltd,
Helsinki, Finland) were designed to detect each individual
mutation using their respective reference sequence. All
PCR reactions were performed in 25 μl volume using
Dynazyme polymerase (Finnzymes, Espoo, Finland) understandard conditions. PCR products were purified using
Exo-SapIT (Affymetrix, Santa Clara, CA) according to the
standard protocol. Sequencing reactions were performed
using Applied Biosystems BigDye terminator v3.1 (Life
Technologies, Carlsbad, CA) and products were analyzed
on the ABI 3730 sequencer. Finally, the accurate genotype
of each variant was confirmed by sequence analysis with
the Sequencher software v4.8 (Life Technologies) in both
the family members and the anonymous Finnish controls.
Primer sequences are available on request.
X-inactivation analysis
X-inactivation study was performed in the families with
symptomatic carrier females. 500 ng of DNA was divided
into two fractions; one set was digested in a 20 μl volume
of buffered solution with HpaII (New England Biolabs,
UK) while the other set was digested with RsaI (Roche,
Basel, Switzerland). Both aliquots were incubated at 37°C
for 17 hours. Next, exon 1 of the androgen receptor gene
(AR) was amplified from 2 μl of each of the HpaII and
RsaI digested DNA samples using the forward 5'-labelled
primer TCCAGAATCTGTTCCAGAGCGTGC and CTG
GGACGCAACCTCTCTC reverse primer [14]. The amp-
lification was performed for 35 cycles with an annealing
temperature of 63.3°C. DNAs from healthy males were
used as controls. Two μl of the PCR product was mixed
with 10 μl of Hi-Di formamide (Life Technologies) and
0.025 μl of GeneScan 500 Liz size marker (Life Technolo-
gies). The samples were run on an ABI3730xl genetic
analyzer. The peaks were analyzed using the GeneMarker
software version1.4 (Life Technologies).
In silico analysis
Multiple programs, including SIFT, PolyPhen-2, PhD-
SNP, PANTHER and SNPs&GO were used to predict
the functional impact of the mutation on the protein
function [15-19].
Multiple protein sequence alignment using orthologous
species and human sequences was performed using
ClustalX to verify the evolutionary conservation of the
respective amino acid positions [20]. The HOPE server
was used to predict the structural effects of the muta-
tion [21]. In addition, we used the ConSeq server to
analyze the evolutionary conservation of the structures
of proteins [22].
Results
Computational analysis of the sequencing data revealed
a total of 1,032 variants in coding and non-coding exons
on chromosome X, or potentially affecting splice sites.
Out of these, 405 protein changing mutations were either
present in publicly available databases or were recurrent
in our in-house dataset. The final set of 25 novel variants
including those that were reported as heterozygous in
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SLC16A2 mutation present in HGMD and the recurrent
variants investigated for segregation in this study are listed
in the Additional file 1: Table S1. In four families,
D299, D174, D172 and D301 a novel mutation in an
X-chromosomal gene was found to co-segregate with
the clinical phenotype. In one family L107, a recurrent
pathogenic mutation in an X chromosomal gene was
identified. In one family D222, a novel missense mutation
in a candidate XLID gene was identified. The clinical phe-
notypes and the identified mutations are described below.
In the remaining eight families no functionally relevant
candidate genes were found.a
c
e
Figure 1 Overview of the mutations reported in SLC16A2 gene in two
pedigree of L107 showing the inheritance of SLC16A2 mutation, open circle
carrier females, empty square denote males, the left half of the black squar
mutation positive males, crossed symbols denote deceased individuals, wt
the missense mutation c.1111C > T, c) Multiple species protein sequence al
pedigree of D299 showing the inheritance of SLC16A2 mutation, e) SangerClinical description of the patients and X-exome sequencing
results
Family L107
Family L107 has three affected males (II-1, II-2 and II-9,
Figure 1a), who presented with moderate to severe ID.
Patients II-1 born in 1950 and II-2 born in 1954 never
walked. They have spastic diplegia in the lower limbs,
athetosis in the upper limbs, alalia and dysarthria. In
contrast, the index patient (II-9) born in 1966 who is the
half-brother could walk but lost his motor skills during
early childhood. Patients II-2 and II-9 could speak a few
words. No data was available from patient II-1 concern-
ing speech. Clinical features are summarized in Table 1.b
d
Finnish families with Allan Herndon Dudley Syndrome. a) Family
s denote females; circles with a dot in the middle denote obligate
es denote affected males, the right half of the squares denote
denote mutation negative subject, b) Sanger sequencing confirming
ignment showing conservation of the mutated R371 residue, d) Family
sequencing confirming the frameshift insertion c.990_991insGCTGC.
Table 1 Overview of the clinical features of the previous
and present families with Allan-Herndon-Dudley
syndrome
Clinical findings Clinical findings
reported previously
D299 L107
Short stature + + -
Scoliosis + + +
Low weight + + +
Microcephaly + + -
Muscle hypoplasia + + NA
Hypotonia + + NA
Contractures + + NA
Dystonic movements + + +
Athetosis + + +
Intellectual disability + +/S +/MO/S
Absent speech + + +
Dysarthria/Limited speech + + +
Seizures + + NA
Pectus excavatum + + NA
Narrow long face + - +
Round face + + -
Valgus + + NA
Hyperreflexia + + NA
Simple ears + + -
Cupped ears + - +
Spastic quadriplegia + + -
MO→Moderate, S→Severe, NA→No data available,+→clinical feature present,
-→clinical feature absent.
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The thyroid hormone levels for TSH and T4 from the
index patient II-9 were within the normal range. Data
about the thyroid hormone level for T3 was unavailable.
The index patient (II-9) was previously analyzed for
MECP2 aberration, as well as for mutations in ARX and
CDKL5, all being normal. High-resolution, X-chromosome
specific arrayCGH was also reported to be normal. X-exome
sequencing of the index patient (II-9) identified a vari-
ant in SLC16A2, BCORL1 and GPR112, respectively.
Variants in BC0RL1 and GPR112 were excluded as they
were not clinically relevant. A missense mutation
[NM_006517.4:c.1111C > T; p.Arg371Cys] in exon 4 of
the SLC16A2 gene was identified and was compatible
with the clinical phenotype. This mutation was also
present in his half-brother (II-2) and his mother (I-2)
was found to be carrier of this mutation. The oldest
affected half-brother (II-1) did not participate in the
mutation analysis study. According to PolyPhen-2, SIFT,
PhD-SNP, SNPS&GO, and PANTHER, the mutation
is predicted to be damaging. The ConSeq server also re-
vealed that this residue is highly conserved with a scoreof 9. Based on HOPE [21], the altered amino acid has a
change in charge and can disturb the ionic interactions
with the other transmembrane helices. The mutant
cysteine residue is more hydrophobic than the wild type
arginine residue, possibly affecting the hydrophobic inter-
actions within the core of the protein or with the mem-
brane lipids and, as a result, disturbing the correct folding
of the protein. The mutation was absent in 100 Finnish
controls.
Family D299
The index patient (III-3) is 16 years old and his two
half-brothers (III-1, III-2) deceased at the ages of 21 years
and 16 years respectively (Figure 1d). Clinical features
are summarized in Table 1.
The three affected sons of family D299 had similar clin-
ical features, characterized by severe psychomotor retard-
ation, absent speech, seizures, hypotonia and contractures.
The thyroid hormone profile of the index patient III-3 was
T3-9 (Normal range: 2.6-5.7 pmol/L), T4-8.6 (Normal range:
9–19 pmol/L), TSH-2.16 (Normal range: 0.35-5 mU/L) and
TGB-870 (Normal range: 233–490 nM/L). The patients
have obtained thyroxin medication at the age of 2–3 years
without any improvement.
X-exome sequencing of the index patient (III-3) revealed
two novel variants, one in SLC16A2 and the other in
ODZ1 (Additional file 1: Table S1). The 5 base-pair inser-
tion identified in exon 3 of SLC16A2 leads to a frameshift
and a premature stop codon [NM_006517.4:c.990_991ins
GCTGC; p.G334PfsX11] and segregated with the clinical
phenotype. The mother (II-2) carries the mutation on one
of her X-chromosomes. The mother's sister (II-5) was also
tested and she was found not to be a carrier. This novel
mutation in the SLC16A2 gene was absent in 100 Finnish
controls.
Family D174
Family D174 has three affected males (III-7, III-8 and
II-5, Figure 2a). The patients aged 36, 35 and 57 years
respectively, are characterized by severe ID with autistic
features, epilepsy, short stature and behavioral problems
such as self injury and aggressive outbursts (Table 2).
X-exome sequencing of the index patient III-8 revealed
a novel missense mutation [NM_000828.4:c.1888G > C;
p.Gly630Arg] in exon 12 of the GRIA3 gene that segre-
gated in the family (Additional file 1: Table S1). The muta-
tion was absent in 135 Finnish controls. Using PolyPhen-2,
SIFT, PhD-SNP, SNPS&GO and PANTHER, the mutation
was predicted to be probably damaging. The ConSeq
server also revealed that this residue is highly conserved
with a score of 9. Missense changes in OR13H1,
GPR112 and F8 did not segregate with the phenotype.
The variants identified in TAF1 and LRCH2 segregated
in the family. However, both variants turned out to be
ac
d
b
Figure 2 Overview of the missense variant reported in GRIA3 in a Finnish Family with XLID. a) Family pedigree showing the inheritance of
the GRIA3 mutation, open circles denote females; circles with a dot in the middle denote obligate carrier females, empty square denote males,
the left half of the black squares denote affected males, the right half of the squares denote mutation positive males, crossed symbols denote
deceased individuals, wt denote mutation negative subject, b) Photographs of the affected males, c) Sanger sequencing confirming the
mutation, d) Multiple species protein sequence alignment showing conservation of the mutated G630 residue.
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present in 3/88 Finnish control samples.
The wild type residue glycine of the p.Gly630Arg is
neutral and the mutant residue arginine is positively
charged. HOPE [21] predicted that this can lead to
disturbances in the ionic interactions with the other
transmembrane helices. The mutant residue is larger
than the wild type residue, which can disturb either
the contacts with the other transmembrane domains
or with the lipid membrane. This can also affect the
hydrophobic interactions within the core of the pro-
tein or with the membrane lipids. The wild type resi-
due, glycine, is considered to be the most flexible of
all residues and this flexibility might be vital for this
protein’s function. It is predicted that this glycine
residue at this position is needed to make a special
backbone conformation or to facilitate movement of
the protein.Family D172
This family has three affected males in two generations
(III-5, III-8 and IV-3, Figure 3a). X-exome sequencing of
the index patient (III-8) revealed two novel variants, one
in DLG3 and the other in ZBTB33 (Additional file 1:
Table S1). The ZBTB33 variant was excluded because it
did not co-segregate with the phenotype. A donor splice
site mutation [NM_021120.3:c.357 + 1G > C] in intron 1
of the DLG3 gene segregates in the family. The affected
males who presented with mild to moderate ID, normal
growth, narrow thorax, molar hypoplasia, short up-
slanting palpebral fissures, a high vaulted palate, and
hypotonia. Daytime wetting has been a problem until
adult age (Table 3). In addition to the aforementioned
features the index patient (III-8) had an external strabis-
mus in his right eye. Chromosomes (300bands), FRAXA,
vacuolated lymphocytes, urinary metabolic screen, oph-
thalmology and hearing examinations showed normal
Table 2 Overview of clinical features of previously published patients with GRIA3 deletion/duplication and present patients with GRIA3 mutation
Gecz et al.
[1999] [31]
Female patient
Wu et al.
[2007] [34]
Male patients
Bonnet et al.
[2009] [36]
Male/male
patient
Chiyonobu et al.
[2007] [35]
Male patient
D174 Male
patient
(III-7)
D174 Male
patient
(III-8)
D174 Male
patient
(II-5)
n = 1 n = 3 n = 2 n = 4 n = 2 n = 2 n = 2 n = 1
Type of change Translocation
t(X;12) (q24;q15)
Deletion Missense
variant
p.G833R
Missense
variant
p.R631S
Missense
variant
p.M706T
Missense
variant
p.R450Q
Partial duplication
of GRIA3
Partial
duplication of GRIA3
Missense
variant
p.G630R
Missense
variant
p.G630R
Missense
variant
p.G630R
Feature
Intellectual disability + + + + + - +/+ + + + +
Mild - - - - + - - - - - -
Moderate + + + + + - - - - - -
Severe - - - - - - +/+ + + + +
Autistic features ND ND + ND ND ND +/ND + + - +
Behaviour troubles + ND + ND ND ND +/+ + + + +
Self injury ND ND ND ND ND ND ND ND + + +
Aggressive outbursts ND ND ND ND ND ND ND ND + + -
Dysmorphic features ND ND ND ND ND ND +/+ + + + +
Brachycephaly ND ND ND ND ND ND ND ND + + +
Macrocephaly ND ND + ND ND ND ND ND - - -
Deep set eyes ND ND ND ND ND ND ND ND + + +
Aesthenic habitus ND ND ND + + ND ND ND - - -
Myclonic jerks ND ND + ND ND ND ND ND ND ND ND
Hyporeflexia ND + ND ND + ND ND ND ND ND ND
Prominent supraorbital ridges ND ND ND ND ND ND ND ND + + +
Short stature ND ND ND ND ND ND -/- + + + +
Epilepsy + ND ND ND ND ND -/- - + + +
Inguinal hernia - ND ND ND ND ND +/- + - - -
Brain MRI abnormalities ND ND ND ND ND ND -/+ - ND ND ND
Bowel occlusions ND ND ND ND ND ND ND ND - - +
Malposition of feet ND ND ND ND ND ND ND ND + + -
Hydronephrosis ND ND ND ND ND ND ND ND + ND ND
Ren arcuatus ND ND ND ND ND ND ND ND + ND ND
ND→No data, +→clinical trait present, -→clinical trait absent.
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Figure 3 Overview of the two splice donor mutations identified in DLG3 in two Finnish families. a) Pedigree of family D172 showing the
inheritance of the DLG3 splice donor mutation c.357 + 1G > C, open circles denote females; circles with a dot in the middle denote obligate
carrier females, empty square show males, the left half of the black squares denote affected males, the right half of the squares denote mutation
positive males, crossed symbols denote deceased individuals, wt denote mutation negative subject, b) Sanger sequencing result showing the
mutation in one affected male, c) Pedigree of family D301 showing the inheritance of the DLG3 splice donor mutation c.985 + 1G > C, d) Sanger
sequencing result showing the mutation in one affected male, e) Schematic representation of the DLG3 gene, along with overview of previously
reported mutations and mutations reported in the current study.
Table 3 Comparison of the clinical features of the patients of two families with DLG3 mutation
Family D172 Family D301
III-5 III-8 IV-3 III-5 III-9 IV-3 V-1 V-2
Male Male Male Male Male Male Male Male
Clinical features
Intellectual disability +/MO +/M +/MO +/S +/S +/MO +/MO +/MO
Delayed motor development + ND + + ND + + +
Delayed speech development + ND + + + + + +
Eneuresis + - + + - - + -
Strabismus - - - + - + + -
ADHD - - - ND ND + + +
Seizures - - - + - - - -
Behavioural problems - - + + - + - -
ND→No data, M→Mild, MO→Moderate, S→Severe, +→clinical feature present, -→clinical feature absent.
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carriers of this mutation. Female III-2 has passed regular
basic education and completed vocational schooling.
Her younger son (IV-5) has epilepsy but is of normal
intelligence and does not have the DLG3 mutation.
Female II-2 is 77 years old, who is also a mutation
carrier and has no cognitive or memory problems. All
females showed a normal X-inactivation pattern in
their blood lymphocytes (data not shown).
Family D301
Family D301 has five affected males in three generations
(III-5, III-9, IV-3, V-1 and V-2, Figure 3c). In the index
patient, V-1, etiological investigations such as urine
metabolic screening, karyotype analysis, Fragile-X test-
ing, FISH on 22q11.2 locus, creatinine kinase, lactate,
carnitine, very long fatty acids, EEG and brain MRI were
normal.
The phenotype consists of delayed motor and language
development. Three males had strabismus and attention
deficit hyperactivity disorder (ADHD). The males do not
have other dysmorphic features except a bifid uvula in
patients V-1 and V-2. Only one patient had experienced
seizures in childhood. The cognitive performance in the
affected males varied from severe to moderate ID, with
ID being less severe in the younger generations (Table 3).
Female III-6 participated in the cognitive evaluation at
the age of 60 years at the level of moderate ID; she had
not been evaluated earlier. She had received her basic
and vocational education in a special school. She has not
been able to work but has lived independently and needs
assistance in all paperwork and contacts with authorities.
The mother (IV-2) of patients V-1 and V-2 and their
grandmother (III-2) graduated from regular schools and
obtained vocational education.
X-exome sequencing of the index patient (V-1) identi-
fied a novel donor splice site mutation [NM_021120.3:
c.985 + 1G > C] in intron 6 of the DLG3 gene (Additional
file 1: Table S1). One affected carrier female (III-6) had a
skewed X-inactivation pattern of 80:20 (Additional file 2:
Figure S1).
Family D222
Family D222 has three affected males who are half-
brothers (III-1, III-2 and III-3, Figure 4a). The phenotype
consists of small gestational age (SGA), hypospadia, mild
aortic stenosis and leakage of the aortic valve, arcus aor-
tae dexter, horseshoe kidney, slenderness and cup
formed ear lobes. Their motor and language develop-
ment were slightly delayed and they continue to have
nocturnal enuresis up to school age. Two of them have
ADHD. The cognitive performance is at the level of mild
ID. The development of the youngest brother (III-4) is
normal (Table 4).X-exome sequencing of the index patient (III-1) identi-
fied novel variants in PTCHD1, RAB40A, ABCD1,
COL4A5 and ZMYM3, respectively (Additional file 1:
Table S1). PTCHD1 and RAB40A were excluded as a
candidate gene because their variants did not segregate
in the family (Additional file 1: Table S1). We suggest
that the variant in COL4A5 is unlikely pathogenic be-
cause mutations in this gene have been previously asso-
ciated with Alport syndrome [OMIM#301050].
The variant in ABCD1 was excluded as a causative
mutation as mutations in ABCD1 previously have been
linked to adrenoleukodystrophy [OMIM#300100]. The
novel missense mutation [NM_201599.2:c.1321C > T;
p.Arg441Trp] in exon 7 of the ZMYM3 gene was
present in all three affected males and absent in their
healthy brother. The mother (II-2) was found to be a
carrier of this mutation. This mutation leads to sub-
stitution of the amino acid arginine with tryptophan
(p.Arg441Trp) and was absent in 100 Finnish anonymous
blood donors.
PolyPhen-2, SIFT, PhD-SNP, SNPS&GO and PAN-
THER predicted this mutation to be damaging. The
ConSeq server also revealed that this residue is highly
conserved with a score of 9. HOPE [21] predicted that
the mutant residue is larger and more hydrophobic than
the wild type residue. The amino acid substitution will
lead to loss of hydrogen bonds in the core of the protein,
thus preventing correct folding. The difference in the
amino acid properties is likely to disturb a Zinc-finger
domain known to bind DNA.
Family D175
This family has 9 affected males in three generations
(II-1, II-13, III-2, III-5, III-11, III-13, III-14, IV-1 and
IV-2, Figure 5a). The affected males are characterized by
mild to moderate ID, normal growth, and dysmorphic
facial features with prominent supraorbital ridges, deep
set eyes, short philtrum, and prominent chin suggesting
a novel syndrome (Figure 5b). One patient has epilepsy
(III-5). Patients III-5, IV-1 and IV-2 have mild brain
abnormalities in MRI (corpus callosum hypoplasia, mild
cortical atrophy). Only limited clinical data is available for
patients III-11, III-13 and III-14.
X-exome sequencing of the index patient (IV-1) identi-
fied a recurrent missense variant in exon 6 of the SYP
gene [NM_003179.2:c.877G > A; p.Gly293Ser]. This mis-
sense variant was found in all the affected males. Vari-
ants in DMD, FAM47A, USP9X variants were not found
in all of the affected males (Additional file 1: Table S1).
Variant in FAM47B was not analyzed.
Discussion
In six families we identified five pathogenic mutations in
three known XLID genes (SLC16A2, GRIA3 and DLG3)
a b
c
d
Figure 4 Clinical presentation of a novel syndrome in a Finnish family with XLID and segregation of the ZMYM3 missense mutation.
a) Pedigree showing the inheritance of the ZMYM3 mutation in family D222, open circles show females, circles with a dot in the middle show obligate
carrier females, empty square show males, the left half of the black squares show affected males, the right half of the squares show mutation positive
males, crossed symbols denote deceased individuals, wt denote mutation negative subject, b) Photographs of the three affected males, c) Sanger
sequencing confirming the mutation, d) Multiple species protein alignment showing conservation of the mutated R441 residue in ZMYM3.
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addition, two novel syndromes were identified, one with
a novel missense mutation in a candidate XLID gene,
ZMYM3 [23] and the other with a previously reported
benign variant in SYP in a large family (D175).Table 4 Summary of clinical findings of patients with the
ZMYM3 mutation
Clinical trait Patient III-1 Patient III-2 Patient III-3
Age 15.5 y 8.8 y 7.3y
Weight at birth 2530 g 2460 g 3590 g
Head circumference 55.5 cm, −1 SD 49.6 cm, −3 SD 49.5 cm, −2.7 SD
Hypospadia + + -
Horseshoe kidney - + -
Enuresis nocturna + + rarely
Large cupped formed
ear lobes
+ + +
ADHD + + ND
Arcus aortae dexter - + -
Bicuspid aortic valve + + -
Sleep disorder + + +
Intellectual disability +/M +/M +/M
M→Moderate, +→clinical trait present, -→clinical trait absent, SD→standard
deviation.We identified two pathogenic mutations in SLC16A2.
Mutations in this gene are known to cause Allan-Herndon-
Dudley syndrome (AHDS; OMIM #300523). AHDS is
typically characterized by developmental delay, poor head
control, poor or no speech and muscle hypoplasia [24]. The
clinical features of the patients investigated in this study are
characteristic of AHDS. Previously, mutations in the
SLC16A2 gene have been reported in more than 45 families
across the world and one de novo translocation t(X;9)
(q13.2;p24) has been reported in a female patient [24-29].
SLC16A2 belongs to the SLC16 gene family [30] and en-
codes the monocarboxylate transporter 8 (MCT8) protein,
which is expressed in brain, liver, heart, intestine, placenta,
kidney and thyroid. In the central nervous system MCT8 is
present in neurons and astrocytes and is an essential
thyroid hormone transporter, involved in the transport of
thyroid hormone (TH) across the blood–brain barrier. The
SLC16A2 gene consists of six exons and encodes a protein
of 539 amino acids [24]. MCT8 contains twelve trans-
membrane domains (TMD) with intracellular amino- and
carboxy-terminal domains [24]. In vitro studies showed that
mutations in this gene lead to a reduced or absent supply
of triiodothyronine (T3) to neurons [30]. The novel frame-
shift mutation p.G334PfsX11 identified in family D299 is
located in the seventh TMD and the recurrent p.Arg371Cys
Figure 5 A clinical presentation of a novel syndrome in a Finnish family (D175) with XLID. a) Family pedigree showing the inheritance of
the benign variant in SYP, open circles denote females, circles with a dot in the middle denote obligate carrier females, empty square denote
males, the left half of the black squares denote affected males, the right half of the squares denote mutation positive males, crossed symbols
denote deceased individuals, wt denote mutation negative subject, b) Photographs of the six affected males, c) Sanger sequencing confirming
the benign variant, d) Multiple species protein alignment showing conservation of the mutated Gly293 residue in SYP, e) Schematic presentation
of the SYP protein domains, location of the published mutations and the polymorphism identified in this study.
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http://www.ojrd.com/content/9/1/49amino acid substitution present in family L107 lies in the
eighth TMD. The same missense mutation has previously
been identified in a sporadic case (annotated as c.1333C >T,
p.Arg445Cys using a different SLC16A2 isoform [29]. It has
been previously shown that in a moderately affected individ-
ual with c.1333C > T missense mutation resulted in a
more severe decrease in T3 uptake [29]. In the article
by Capri et al. [29], the affected patient, aged 13 years,
is able to walk with aid and can speak a few words. In
family L107 the phenotype is variable as the two oldest
patients (II-1 and II-2) never walked whereas the youngest
II-9 could walk until early childhood. The patients in
family L107 could speak some words. Based on the available
data p.Arg445Cys mutation seems to be associated with
variable phenotypes. To our knowledge, these are the first
families with AHDS in the Finnish population.
We identified a missense mutation c.1888G >C (p.
Gly630Arg) (RefSeq NM_000828.4) in the glutamate
receptor, ionotropic, AMPA 3 (GRIA3) gene. GRIA3 belongs
to a class of an alpha-amino-3-hydroxy-5-methyl-4-isoxa-
zole propionate (AMPA)-sensitive glutamate receptor that
operates as a ligand-gated ion channel in the central nervoussystem and has an essential role in excitatory synaptic trans-
mission [31]. These receptors contain three functional
domains – transmembrane, ligand binding, and receptor
channel core [32]. Ionotropic glutamate receptors (iGluRs)
are related to learning and memory [33]. In vitro functional
studies on GRIA3 missense variants have shown that muta-
tions in functional domains of GRIA3 are associated with
kinetic changes in AMPA receptor function leading to
significant reduction in iGluR3 channel function which is
found to be linked with moderate ID [34,35]. Previously,
four missense mutations, one whole gene deletion and three
duplications have been reported in GRIA3 [34-38]. One of
the missense mutations (p.Arg631Ser) [34] affected the
amino acid residue adjacent to the Gly630 mutated in the
family described here. The patients of these families have
facial dysmorphic features in common and these are differ-
ent from the other reported patients with a mutation in
GRIA3. The affected individuals of family D174 exhibit a
severe phenotype. They are all severely intellectually disabled
with behavioral disturbances. Three of the four previously
reported patients with a GRIA3 mutation were moderately
intellectually disabled, whereas one patient with a missense
Philips et al. Orphanet Journal of Rare Diseases 2014, 9:49 Page 11 of 13
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there is wide variation in the severity of ID among patients
with mutations in the GRIA3 gene. Further phenotype stud-
ies are needed to confirm the syndromic features underlying
GRIA3mutations.
The DLG3 gene, located at Xq13.1, encodes the synapse-
associated protein SAP102 [39]. SAP102 is a member of the
membrane-associated guanylate kinase (MAGUK) protein
family [39,40]. SAP102 is highly expressed in both young
and mature neurons and localizes to the postsynaptic dens-
ity of excitatory synapses [41]. It is the first XLID gene to be
associated to glutamate receptor-mediated postsynaptic
signaling, a process which is crucial for the regulation of
synaptic formation and plasticity in brain development [40].
Mutated DLG3 has been identified as a rare cause of XLID
with, so far, only five families diagnosed, with a total of 17 af-
fected males presenting with moderate to severe ID [41,42].
Of eleven mutation carrier women, one has mild ID and in
another family a female carrier has mild ID and a history of
seizures. These expressing females, however, do not have a
skewed X-inactivation pattern [41,42]. Our families expand
the phenotype spectrum of DLG3mutations to mild ID.
The missense mutation c.1321C >T (p.Arg441Trp)
(RefSeq NM_201599.2) is the first variant in the coding
region of ZMYM3 reported to date. Previously, a chromo-
somal breakpoint in the 5’ UTR of ZMYM3 has been
reported in an intellectually disabled female. In addition to
ID, the patient had scoliosis and spotty hyperpigmentation
of the skin. She also had slight facial asymmetry and clino-
dactyly [23]. However, the patients described in this study
do not have any of the reported clinical features except for
mild ID. Recently, a missense variant of unknown signifi-
cance (c.356A >G (p.Gln119Arg)) in ZMYM3 was reported
in the index patient of a family with XLID with four affected
males in two generations. However, the patient also carries a
missense change in the established XLID gene HCFC1 [43].
The ZMYM3 gene is also referred to as ZNF261 and
DXS6673E. ZMYM3 belongs to the MYM family. This
gene contains 5 tandem repeats of a Cys-X2-Cys-X19–22-
Cys-X3-Cys-X3-Cys-X13–19-Cys-X2-Cys-X19–25-Cys-X3-Cys
motif [44]. ZMYM3 encodes a protein that is an integral
component of histone deacetylase-containing multiprotein
complexes. Further clarification is needed regarding the
role of ZMYM3 as a XLID gene [45]. In addition, a
previously reported benign polymorphism in SYP was
identified in six affected males with a syndromic
phenotype (Additional file 1: Table S1). Pathogenic
mutations in SYP, including three truncating and one
missense change (OMIM #300802) have previously been re-
ported [11]. The patients in our study presented with mild
to moderate ID, epilepsy, and common dysmorphic features.
The missense benign variant c.877G >A (p.Gly293Ser)
(RefSeq NM_003179.2) has been reported in the Exome
Variant Server with a MAF frequency of T = 0.001/1suggesting that SYP is not explaining the syndromic
phenotype in this large family.
The diagnostic yield based on our current study of 14
families is 35%, of which five pathogenic mutations are
likely to be disease causing. The role of ZMYM3 as a XLID
gene is still questionable and can further be substantiated
by the identification of additional families and mutations.
In eight families, work is ongoing as a functionally
relevant mutation has not yet been identified. This might
be due to technical limitations or a non-X-chromosomal
origin of the disorders. In five of the mutation “negative”
families the affected are brother pairs, in which linkage
is less strong than for the other families.
Conclusions
The first X-exome sequencing study of Finnish families
with intellectual disability revealed the first two Finnish
families with Allan-Herndon-Dudley syndrome, one
family with a novel mutation in GRIA3, and two families
with novel mutations in DLG3. In addition, a novel mis-
sense mutation in the candidate XLID gene ZMYM3 co-
segregated with a novel syndrome. A seventh family was
found to have a benign missense variant SYP and a syn-
dromic phenotype. Further studies are needed to find
the causative mutation in this extended family.
This study demonstrates the power of exome sequencing
in finding rare mutations underlying intellectual disability.
It has been estimated that roughly 10% of the protein cod-
ing genes causing ID are located on the X-chromosome.
Based on our research results, the likelihood of finding a
genetic cause for the disease is increased in families with
several affected males. We hypothesize that in some of the
families, rare autosomal recessive mutations may be identi-
fied due to the characteristics of the founder population of
Finland [46].
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